Zevra Therapeutics reported a significant financial turnaround for the nine months ended September 30, 2026, with net income of $65.85 million compared to a net loss of $72.26 million in the prior year period. This improvement was driven by a 57% increase in net revenue and a $43.3 million gain on the sale of future royalties and intellectual property.
Zevra Therapeutics reported Q3 2026 net revenue of $37.8 million, a 45% increase year-over-year, primarily driven by $34.0 million in sales from MIPLYFFA. The company achieved net income of $19.2 million for the quarter and maintained a strong cash position of $270.9 million to support its rare disease pipeline.
Term
Q3 2026
“In the third quarter, we made continued progress across our business, building on MIPLYFFA's commercial performance in the U.S. and advancing our pipeline in support of our mission to redefine what’s possible in bringing life-changing therapies to people living with rare disease.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer
“We remain focused on reaching more people living with Niemann-Pick disease type C, advancing celiprolol for vascular Ehlers-Danlos syndrome, and pursuing European access to arimoclomol. Our strong financial position enables us to advance these priorities while continuing to make arimoclomol available to eligible patients through our global Expanded Access Program.”
Neil F. McFarlane, Zevra's President and Chief Executive Officer